冉明东 吴锦葭(中南财经政法大学 湖北省医疗保障改革发展研究院)2025年5月,一纸公告在全球医药圈掀起涟漪:三生制药将一款尚处临床阶段的PD-1/VEGF双抗候选药物,以首付款12.5亿美元、总金额60.5亿美元授权给辉瑞,创下国产创新药出海的新纪录。6月2日,普米斯生物开发的PD-L1/VEGF双抗PM8002,继被BioNTech收购后,又以111亿美元的高价转授百时美施贵宝(BMS),完成...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.